Ossium Health Reports Promising Early Results for Deceased Donor Bone Marrow Transplants in Hematologic Malignancies
核心洞察
Ossium Health (搜索) presented clinical data from four patients with hematologic malignancies (搜索) who received hematopoietic stem cells from deceased organ donor vertebral bodies, with all achieving rapid neutrophil engraftment and platelet recovery.
By Day 180 post-transplant, all evaluatable patients remained alive and relapse-free, with acute GVHD (搜索) successfully managed using steroids (搜索) and no chronic GVHD (搜索) reported.
The company's PRESERVE I study represents the first-in-human clinical experience with off-the-shelf cryopreserved bone marrow (搜索) from deceased donors, demonstrating safety and feasibility.
Ossium Health (搜索) has reported encouraging early clinical results from its groundbreaking approach to bone marrow (搜索) transplantation using deceased organ donors, presenting data at the 66th American Society of Hematology (ASH) Annual Meeting that could address longstanding challenges in hematopoietic cell transplantation.
The bioengineering company presented clinical data from four patients with hematologic malignancies (搜索) who were treated with hematopoietic stem cells derived from the vertebral bodies of deceased organ donors. All four patients achieved rapid neutrophil engraftment, platelet recovery, and full donor chimerism, marking a significant milestone for this novel transplant approach.
Clinical Outcomes Show Promise
The early results from Ossium's clinical program demonstrate robust engraftment capabilities while addressing key transplant complications. All cases of acute graft-versus-host disease (搜索) (GVHD) were successfully managed with steroids (搜索), and notably, no chronic GVHD (搜索) was reported in the patient cohort. By Day 180 post-transplant, all evaluatable patients remained alive and relapse-free.
"These early results indicate that Ossium's deceased-donor-derived bone marrow (搜索) is a promising new graft source that supports robust engraftment while addressing both relapse and GVHD prevention," according to the company's clinical data presentation.
PRESERVE I Study Advances Off-the-Shelf Transplantation
Ossium's ongoing PRESERVE I study represents the first-in-human clinical experience with HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow (搜索) transplantation. Dr. Sagar Munjal, Ossium's Chief Medical Officer, has presented the study's preliminary data demonstrating the safety and feasibility of transplanting bone marrow derived from deceased donors.
The clinical program highlights key advantages of Ossium's platform, including its ability to provide immediate graft availability in urgent scenarios when a living donor becomes unavailable. This capability addresses a critical unmet need in transplant medicine, where donor availability limitations can delay life-saving treatments.
Addressing Critical Transplant Challenges
Kevin Caldwell, Ossium's CEO, Co-Founder & President, emphasized the transformative potential of the technology: "Our findings demonstrate the potential of organ donor bone marrow (搜索) to transform patient outcomes." The company's approach aims to improve access, speed, and quality in hematopoietic cell transplantation by overcoming longstanding donor availability limitations.
The clinical data suggests that high-dose cryopreserved bone marrow (搜索) from deceased donors may reduce relapse risk in HLA-mismatched allogeneic transplantation, potentially offering therapeutic advantages over traditional donor sources. Ossium has also demonstrated the feasibility of refreezing previously cryopreserved bone marrow following reprocessing, adding operational flexibility to the platform.
Growing Clinical Evidence
Ossium's presentations at major hematology conferences underscore the growing clinical body of evidence supporting the feasibility, safety, and transformative potential of deceased donor bone marrow (搜索). The company has successfully demonstrated lifesaving graft rescue capabilities using off-the-shelf cryopreserved cadaveric marrow in myeloablative transplant settings when living matched unrelated donors unexpectedly became unavailable.
"These presentations highlight the growing clinical body of evidence supporting the feasibility, safety, and transformative potential of Ossium bone marrow (搜索)," Caldwell stated, reflecting the company's commitment to advancing this novel therapeutic approach through continued clinical development and engagement with the transplant community.